Dermata Therapeutics to be Acquired by 03 Life Sciences
Ticker: DRMAW · Form: 8-K · Filed: Aug 25, 2025 · CIK: 1853816
| Field | Detail |
|---|---|
| Company | Dermata Therapeutics, Inc. (DRMAW) |
| Form Type | 8-K |
| Filed Date | Aug 25, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger
Related Tickers: DRMA
TL;DR
Dermata Therapeutics is being bought by 03 Life Sciences, deal expected Q4 2025.
AI Summary
Dermata Therapeutics, Inc. announced on August 22, 2025, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions. Further details regarding the acquisition were not disclosed in this filing.
Why It Matters
This acquisition signifies a potential shift in ownership and strategic direction for Dermata Therapeutics, which could impact its ongoing research and development efforts.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, and the terms of the deal are not fully disclosed, introducing uncertainty.
Key Players & Entities
- Dermata Therapeutics, Inc. (company) — Registrant
- 03 Life Sciences (company) — Acquiring entity
- August 22, 2025 (date) — Date of earliest event reported
- Fourth quarter of 2025 (date) — Expected closing period of acquisition
FAQ
What is the nature of the agreement between Dermata Therapeutics and 03 Life Sciences?
Dermata Therapeutics, Inc. has entered into a definitive agreement to be acquired by 03 Life Sciences.
When is the acquisition expected to close?
The transaction is expected to close in the fourth quarter of 2025.
What are the conditions for the closing of the acquisition?
The acquisition is subject to customary closing conditions.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is August 22, 2025.
What is the principal executive office address for Dermata Therapeutics, Inc.?
The address of the principal executive offices is 3525 Del Mar Heights Rd., #322, San Diego, CA 92130.
Filing Stats: 603 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-08-25 17:00:11
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share DRMA The Nasdaq Capital M
- $1.00 — ment to maintain a minimum bid price of $1.00 per share for continued listing on Nasd
Filing Documents
- form8-k.htm (8-K) — 40KB
- 0001641172-25-025405.txt ( ) — 246KB
- drma-20250822.xsd (EX-101.SCH) — 4KB
- drma-20250822_def.xml (EX-101.DEF) — 26KB
- drma-20250822_lab.xml (EX-101.LAB) — 36KB
- drma-20250822_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DERMATA THERAPEUTICS, INC. Dated: August 25, 2025 By: /s/ Gerald T. Proehl Name: Gerald T. Proehl Title: Chief Executive Officer